12 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
Accrued expenses and other current liabilities consists of the following (in thousands):
March 31, 2024 | December 31, 2023 | |||||||
Rebates, chargebacks, other customer fees and returns | $ | 84,803 | $ | 66,726 | ||||
Clinical accruals | 26,536 | 22,459 | ||||||
Contract manufacturing | 3,140 | 4,356 | ||||||
Commercial services | 5,309 | 6,900 | ||||||
Employee related expenses | 5,531 | 11,598 | ||||||
Other taxation and social security | 5,774 | 1,807 | ||||||
Other accruals | 7,456 | 5,989 | ||||||
$ | 138,549 | $ | 119,835 |
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
For the three months ended March 31, 2024, our SG&A expenses were $39.3 million, as compared to $32.6 million for the three months ended March 31, 2023, reflecting an increase of $6.7 million. SG&A expenses for three months ended March 31, 2024 and 2023 comprised the following (in thousands):
Three Months Ended March 31, | ||||||||||||||||
2024 | 2023 | Increase / (decrease) | % Increase / (decrease) | |||||||||||||
Share-based compensation expense | $ | 6,984 | $ | 6,562 | $ | 422 | 6.4 | % | ||||||||
Salaries and other employee-related costs | 14,840 | 9,244 | 5,596 | 60.5 | % | |||||||||||
Selling and commercial costs | 10,649 | 10,244 | 405 | 4.0 | % | |||||||||||
Other administrative expenses | 6,814 | 6,517 | 297 | 4.6 | % | |||||||||||
Total SG&A expenses | $ | 39,287 | $ | 32,567 | $ | 6,720 | 20.6 | % |
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
The following table summarizes our R&D expenses (in thousands):
Three Months ended March 31, | ||||||||||||||||
2024 | 2023 | Increase / (decrease) | % Increase / (decrease) | |||||||||||||
External R&D expenses: | ||||||||||||||||
Tebentafusp programs | $ | 5,894 | $ | 4,121 | $ | 1,773 | 43.0 | % | ||||||||
PRAME programs | 26,700 | 8,795 | 17,905 | 203.6 | % | |||||||||||
Infectious disease programs | 2,246 | 1,748 | 498 | 28.5 | % | |||||||||||
All other external clinical and pre-clinical costs | 6,499 | 4,526 | 1,973 | 43.6 | % | |||||||||||
Total external R&D expenses | 41,339 | 19,190 | 22,149 | 115.4 | % | |||||||||||
Internal R&D expenses: | ||||||||||||||||
Salaries and other employee-related costs | 9,754 | 9,180 | 574 | 6.3 | % | |||||||||||
Share-based compensation expense | 1,980 | 1,696 | 284 | 16.7 | % | |||||||||||
All other internal R&D costs | 6,209 | 7,237 | (1,028) | (14.2 | )% | |||||||||||
U.K. R&D tax credits | (1,823) | (731) | (1,092) | 149.4 | % | |||||||||||
Total internal R&D expenses | 16,120 | 17,382 | (1,262) | (7.3 | )% | |||||||||||
Total R&D expenses | $ | 57,459 | $ | 36,572 | $ | 20,887 | 57.1 | % |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
For 2023, our corporate scorecard was comprised of performance objectives in three categories, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied to workplace improvement metrics. The goals summarized below for each metric were selected by the remuneration committee based on the remuneration committee’s determination that each was important for our short- and long-term success. The remuneration committee set threshold (75% achievement for partially meeting the goal), target (100% achievement for meeting the goal) and maximum (125% achievement for exceeding the goal) performance levels for each goal. When it approved the 2023 performance objectives, the remuneration committee believed that achievement of target performance would be reasonably challenging based upon industry-wide conditions and our internal forecasts at the time. Further, the performance objectives were set within the backdrop of a difficult environment due to the Ukraine and Israel-Hamas wars and global geopolitical tensions. Our 2023 corporate scorecard and the relevant performance levels are summarized, for market factors and competitive reasons, below. The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
| | | | Initial Calculated Achievement | | | 101% | |||||
| | | | Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | 110% |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
Initial Calculated Achievement | | | | | 101% | |||||||
| | | | | | | | |||||
Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | | | 110% |
DEF 14A
jlm9gr1mjh 8aflnl6qs
12 Apr 24
Definitive proxy
4:20pm
10-K
noj8aezz8 my2u
28 Feb 24
Annual report
7:33am
10-K
gindbb49wa6qu
28 Feb 24
Annual report
7:33am
10-K
rtps4d62b9tgqfz8
28 Feb 24
Annual report
7:33am
10-K
bwzx 15n0xop8
28 Feb 24
Annual report
7:33am
10-K
a4kti1z88xihthv2j
28 Feb 24
Annual report
7:33am
10-K
hcbbc3jq
28 Feb 24
Annual report
7:33am
- Prev
- 1
- Next